A trial looking at cabozantinib for primary liver cancer that had got worse despite having sorafenib

This trial looked at cabozantinib for people with the most common type of primary liver cancer called hepatocellular carcinoma or HCC.

It was for people who had already had the cancer drug sorafenib.

This trial was open for people to join between 2013 and 2017. The trial team published the results in 2018.